Can the further clinical development of bevirimat be justified?
Mark A
MA
Wainberg
Jan
J
Albert
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D017277:Drug Approval / Q000379:methods; D015195:Drug Design; D024882:Drug Resistance, Viral; D006801:Humans; D013386:Succinates / Q000627:therapeutic use*; D014315:Triterpenes / Q000627:therapeutic use*; D053978:Pentacyclic Triterpenes
D019380:Anti-HIV Agents; D013386:Succinates; D014315:Triterpenes; C479935:bevirimat; D053978:Pentacyclic Triterpenes